Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026)

Lexeo Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 21144000.0 in Q1 2026.

• Quarterly Cash from Operations rose 2.63% year-over-year to 21144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97989000.0 (down 11.35% YoY) and the FY2025 annual result came in at 98561000.0, down 21.45% from the prior year.
• Cash from Operations eased to 21144000.0 in Q1 2026 per LXEO's latest filing, from 20079000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 13192000.0 in Q2 2023 and troughed at 29547000.0 in Q3 2025.
• A 5-year average of 19784142.86 and a median of 19226500.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 102.6% in 2024, then gained 29.11% in 2025.
• Over 5 years, Cash from Operations stood at 16626000.0 in 2022, then grew by 15.91% to 13981000.0 in 2023, then slumped by 102.6% to 28326000.0 in 2024, then increased by 29.11% to 20079000.0 in 2025, then fell by 5.3% to 21144000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 21144000.0, 20079000.0, and 29547000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.